Blue Jet Health

Why is Blue Jet Healthcare Ltd falling/rising?

As of 12-Jun, Blue Jet Healthcare Ltd's stock is rising to Rs 512.65, up 2.85% with strong recent performance and increased investor participation. However, the company faces long-term challenges with a 46.80% decline in stock returns over the past year and poor financial results.

As of 12-Jun, Blue Jet Healthcare Ltd's stock price is rising, currently at Rs 512.65, reflecting a change of 14.2 (2.85%) upward. The stock has shown a strong performance over the past week, gaining 10.24%, and has risen 9.14% over the last two days. This upward movement is supported by a significant increase in investor participation, with delivery volume rising by 357.67% compared to the 5-day average. Additionally, the medical equipment sector, in which the company operates, has gained by 3.85%, contributing to the positive sentiment around the stock.<BR><BR>Despite these short-term gains, the company faces challenges in the long term, as indicated by its negative performance over the past year, with a decline of 46.80% in stock returns. The company has reported poor financial results, including a fall in profit before tax (PBT) and net sales, which have grown at negative rates over the past nine months. Furthermore, while the stock is currently trading higher than its short-term moving averages, it remains below its 200-day moving average, suggesting potential volatility.<BR><BR>In summary, Blue Jet Healthcare Ltd's stock is rising due to recent positive performance metrics and increased investor interest, despite underlying financial challenges that may affect its long-term growth prospects.

Which are the latest news on Blue Jet Health?

What does Blue Jet Health do?

Blue Jet Healthcare Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of ₹235 Cr and a net profit of ₹64 Cr for March 2026. It was incorporated in 1968 and rebranded in 2022, with a market cap of ₹8,220 Cr.

Overview: <BR>Blue Jet Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>The company was originally incorporated as Jet Chemicals Private Limited in 1968. It changed its name to Blue Jet Healthcare Private Limited in December 2020 and later became a Limited Company with the current name on May 18, 2022. The latest quarterly results report net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 235 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 64 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 8,220 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 33.00 <BR>Industry P/E: 92 <BR>Dividend Yield: 0.25% <BR>Debt-Equity: -0.25 <BR>Return on Equity: 18.22% <BR>Price to Book: 6.02 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Blue Jet Health?

As of 10th June, Blue Jet Healthcare Ltd has a market capitalization of 8,220.00 Cr, with recent net sales of 947.32 Cr and a net profit of 247.82 Cr.

As of 10th June, Blue Jet Healthcare Ltd has a market capitalization of 8,220.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, Blue Jet Healthcare Ltd reported Net Sales of 947.32 Cr and a Net Profit of 247.82 Cr.<BR><BR>The latest annual period for the balance sheet is March 2021, with Shareholder's Funds amounting to 339.82 Cr and Total Assets of 536.27 Cr.

Who are in the management team of Blue Jet Health?

The management team of Blue Jet Health includes Executive Chairman Akshay Bansarilal Arora, Managing Director Shiven Akshay Arora, Executive Director Naresh Suiyakant Shah, and several Independent Directors: Girish Paman Vanvari, Preeti Mehta, and Divya Momaya, along with Company Secretary Sweta Poddar. They are responsible for the company's strategic direction and operations.

The management team of Blue Jet Health includes the following key individuals:<BR><BR>1. **Akshay Bansarilal Arora** - Executive Chairman<BR>2. **Shiven Akshay Arora** - Managing Director<BR>3. **Naresh Suiyakant Shah** - Executive Director<BR>4. **Girish Paman Vanvari** - Independent Director<BR>5. **Preeti Mehta** - Independent Director<BR>6. **Divya Momaya** - Independent Director<BR>7. **Sweta Poddar** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Blue Jet Health?

Blue Jet Health's peers include P & G Health Ltd, Akums Drugs, Strides Pharma, Supriya Lifesci, Sanofi India, SPARC, FDC, and Aarti Pharma. Most peers have Below Average growth, with Supriya Lifesci showing the highest 1-year return at 43.14%, while Blue Jet Health has the lowest at -47.20%.

Peers: The peers of Blue Jet Health are P & G Health Ltd, Akums Drugs, Strides Pharma, Supriya Lifesci., Sanofi India, SPARC, FDC, and Aarti Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at P & G Health Ltd and Sanofi India, while Good management risk is found at Blue Jet Health and Supriya Lifesci. Average management risk is present at Akums Drugs, Strides Pharma, SPARC, FDC, and Aarti Pharma. All peers exhibit Below Average growth except for SPARC, which has Excellent growth, while the rest have Below Average growth. Capital Structure is Excellent at P & G Health Ltd, Blue Jet Health, Sanofi India, Supriya Lifesci., and Aarti Pharma, while Good is found at Akums Drugs, and Below Average at Strides Pharma and SPARC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Supriya Lifesci. at 43.14%, while Blue Jet Health has the lowest at -47.20%. Blue Jet Health's 1-year return is significantly lower than all peers. Additionally, Sanofi India and Aarti Pharma have negative six-month returns.

Should I buy, sell or hold Blue Jet Healthcare Ltd?

Are Blue Jet Healthcare Ltd latest results good or bad?

Blue Jet Healthcare Ltd's latest results are concerning, showing a 41.56% year-on-year decline in net profit and a 31.07% drop in revenue for Q4 FY26, despite some sequential improvements. Overall, these results indicate significant operational challenges for the company.

Blue Jet Healthcare Ltd's latest results indicate a challenging situation for the company. In the fourth quarter of FY26, the company reported a net profit of ₹64.34 crore, which is a significant decline of 41.56% year-on-year compared to ₹110.10 crore in the same quarter of the previous year. Revenue also fell sharply, with Q4 FY26 revenue at ₹234.67 crore, down 31.07% from ₹340.45 crore in Q4 FY25.<BR><BR>While there was a sequential improvement in both revenue and net profit compared to the previous quarter (up 21.96% and 60.17% respectively), the year-on-year comparisons reveal deeper issues. The operating margin decreased significantly, from 41.12% in Q4 FY25 to 30.37% in Q4 FY26, indicating pressure on profitability.<BR><BR>Overall, the results reflect a company under considerable operational stress, with declining revenues and profits year-on-year, despite some signs of recovery on a quarter-to-quarter basis. This combination of factors suggests that the latest results are more indicative of challenges than successes for Blue Jet Healthcare.

When is the next results date for Blue Jet Healthcare Ltd?

The next results date for Blue Jet Healthcare Ltd is 25 May 2026.

The next results date for Blue Jet Healthcare Ltd is scheduled for 25 May 2026.

Is Blue Jet Health overvalued or undervalued?

As of November 25, 2025, Blue Jet Health is considered very expensive and overvalued, with a PE ratio of 27.80 and lagging behind the Sensex with a year-to-date return of -0.49%.

As of 25 November 2025, Blue Jet Health's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 27.80, an EV to EBIT of 22.46, and a Price to Book Value of 7.80, all of which suggest a high valuation relative to earnings and asset value.<BR><BR>In comparison to its peers, Blue Jet Health's valuation metrics are notably elevated; for instance, Poly Medicure has a PE ratio of 53.35 and an EV to EBITDA of 40.61, while Vimta Labs shows a PE of 44.86 and an EV to EBITDA of 24.04, both categorized as very expensive. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -0.49% compared to the Sensex's 8.25%, reinforcing the notion of overvaluation.

Is Blue Jet Health technically bullish or bearish?

As of November 3, 2025, Blue Jet Health's technical trend has shifted to a moderately bearish stance, indicated by a bearish MACD, moving averages, and Bollinger Bands, suggesting a negative outlook in the near term.

As of 3 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Blue Jet Health is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a mildly bearish reading on the weekly Bollinger Bands. Additionally, the Dow Theory indicates a mildly bearish trend on the weekly chart. Overall, the combination of these indicators suggests a negative outlook for the stock in the near term.

How has been the historical performance of Blue Jet Health?

Blue Jet Health experienced a decline in net sales and profit from March 2020 to March 2021, with net sales dropping to 498.93 Cr from 538.20 Cr and profit after tax decreasing to 135.79 Cr from 144.96 Cr. Despite this, the company saw an increase in total assets and a significant rise in cash inflow.

Answer:<BR>The historical performance of Blue Jet Health shows a decline in net sales and profit from March 2020 to March 2021.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2021, Blue Jet Health reported net sales of 498.93 Cr, down from 538.20 Cr in the previous year. Total operating income also decreased to 498.93 Cr from 538.20 Cr. The raw material cost rose to 214.27 Cr from 186.60 Cr, while the total expenditure, excluding depreciation, fell to 292.88 Cr from 324.47 Cr. Operating profit (PBDIT) decreased slightly to 214.93 Cr from 219.54 Cr, and profit before tax declined to 184.66 Cr from 194.13 Cr. Consequently, profit after tax also dropped to 135.79 Cr from 144.96 Cr. The earnings per share (EPS) saw a significant reduction, falling to 27.4 from 483.2. On the balance sheet, total liabilities increased to 536.27 Cr from 373.85 Cr, while total assets rose to 536.27 Cr from 373.85 Cr. The company experienced a net cash inflow of 51.00 Cr in March 2021, compared to 5.00 Cr in March 2020, with closing cash and cash equivalents increasing to 61.00 Cr from 10.00 Cr.

Who are the top shareholders of the Blue Jet Health?

The top shareholder of Blue Jet Health is Akshay Bansarilal Arora, holding 68.99%. Other shareholders include mutual funds at 0.5%, foreign institutional investors at 1.97%, and individual investors with a collective holding of 8.03%.

The top shareholders of Blue Jet Health include the promoters, with Akshay Bansarilal Arora being the individual with the highest holding at 68.99%. Additionally, the company has mutual funds holding 0.5% through 8 schemes and foreign institutional investors (FIIs) holding 1.97% across 53 FIIs. Individual investors collectively hold 8.03% of the shares. There are no significant public shareholders listed.

Has Blue Jet Health declared dividend?

Yes, Blue Jet Healthcare Ltd has declared a 50% dividend, amounting to 1 per share, with an ex-date of September 17, 2024. While the company has shown strong price returns of 80.89% over the last six months and 141.24% over the past year, dividend returns remain minimal.

Blue Jet Healthcare Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 1 per share<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.11%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 80.89%, with no dividend return, resulting in a total return of 80.89%.<BR><BR>Over the past year, the price return reached 141.24%, with a dividend return of 0.27%, leading to a total return of 141.51%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, there were no price or dividend returns, leading to a total return of 0.0%.<BR><BR>For the 4-year period, the price return and dividend return were both 0%, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Blue Jet Healthcare Ltd has declared a dividend, the company has shown significant price returns over the past year and six months, but the dividend returns have been minimal in comparison.